Learn more about the manufacturing process of biotherapeutics and the current challenges they face in this graphic from the International Federation for Pharmaceutical Manufacturers and Associations (IFPMA).
Undoubtedly, one innovation that has radically transformed medicines is the development of newer, more sophisticated type of drugs produced by living organisms called biotherapeutics. More than 350 biotherapeutic medicines have benefited to date some 400 million patients worldwide. Biotherapeutics lead to more targeted therapies, better diagnostics, and improved outcomes following a patient’s course of treatment for many of the world’s most prevalent diseases, as well as for less common conditions.
Biotherapeutics include innovative products for the treatment of chronic diseases such as cancer, diabetes, and rheumatoid arthritis, as well as for acute conditions such as myocardial infarction and stroke—and have two common denominators: biological origin and structural complexity. These products bring genuine differences in saving lives, reducing hospitalization, and, ultimately, contributing to healthier societies.